Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. - Wikidata - wikimedia - TriplyDB

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

http://www.wikidata.org/entity/Q43040369

about

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C Hepatitis C virus protease inhibitor-resistance mutations: our experience and review Recent Advances in Antiviral Therapy for Chronic Hepatitis C KASL clinical practice guidelines: management of hepatitis C Ribavirin: Past, present and future Psychosocial assessment and monitoring in the new era of non-interferon-alpha hepatitis C virus treatments The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment Tangible resources for preparing patients for antiviral therapy for chronic hepatitis C Chutes and ladders in hepatitis C nucleoside drug development Interleukin-1 Inhibits Hepatitis C Virus Subgenomic RNA Replication by Activation of Extracellular Regulated Kinase Pathway Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C Erythropoietin and hepatitis C therapy: useful adjuvant therapy but remember to treat the patient and not just a number Expert opinion on the treatment of patients with chronic hepatitis C Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: A prospective, real-life, observational study Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition Four-week pegylated interferon a-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: A pilot, randomized study Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence Hepatitis C: a clinical review Hepatitis C Virus (HCV) Quasispecies Complexity and Selection in HCV/HIV‐Coinfected Subjects Treated with Interferon‐Based Regimens Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: meta-analysis of randomized, double-blind, placebo-controlled trials?Correlates of Initiation of Treatment for Chronic Hepatitis C Infection in United States Veterans, 2004-2009 ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection Challenges in the treatment of HIV and HCV coinfection.Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients.An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.Management of rare side effects of peginterferon and ribavirin therapy during hepatitis C treatment: a case report.Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: an open-label pilot study.Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.Platelet count and sustained virological response in hepatitis C treatment.Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C.Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy.Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection.Sustained viral response and treatment-induced cytopenia correlate with SLCs and KLF12 genotypes in interferon/ribavirin-treated Chinese chronic hepatitis C patients.Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis.

P2860

Q24200189-CE595998-3E19-4347-9540-E3E6CC26F060 Q24201588-2842C00B-FCDD-42EE-AC5A-009B25D20635 Q24628717-0CF8C817-1CAD-463C-B8B0-3A98A134975E Q26750476-213EF5DC-44E9-41FD-92E0-8E6711016D28 Q26752471-F4E96E9E-B332-412F-A8B0-19199F620DA7 Q26775002-B9AE8B8E-5A33-42F4-9E5E-07D7CA9AB194 Q26784261-966D45AF-3578-4978-9BAC-9F0CAB330033 Q26795559-B14CE6E5-CF94-41FF-8659-8549D04943C3 Q26858962-A64F0786-BE4F-433C-8B37-B7E3161E46C9 Q26998630-3723F269-5199-41C5-8E39-423CCC1E3755 Q27473476-75EAE74E-5C7F-4841-9757-8F09F8CDFB4E Q27477533-01838D23-5840-4076-BFF4-C0E230DAE1ED Q27478337-7E333975-8FF8-4610-9743-8599CA66993D Q27488244-447BAF4A-82FF-4FFE-B7CA-750AF5237D6D Q27489903-BEB26D0B-37B1-49F0-8418-719B8F75A84A Q27490163-97016379-B323-4E7A-9E53-CC00258C8BF9 Q27490340-3AAFA37E-EF3C-469C-81BC-21726F569CD6 Q27490396-425D773E-6B95-42B2-8B1E-7E9B304CD545 Q27490399-95C1BC0D-9DB7-4823-86AC-8D497688C1B9 Q27490405-251CB9BD-7A29-4646-B760-BC60388756E4 Q27490788-79C13AA1-3AD9-4FDD-B037-BC8C1A7B9912 Q27490972-47F6728B-FEF7-4DC4-A8C1-AEF92668FCC3 Q28254011-61DC6DEC-4260-402B-B4DE-ECC7B0DCA4FB Q28534735-7C3D31AF-9525-4CD9-85DB-54724996A587 Q28546457-0FF46F7F-D0EF-408F-A6FF-93FA7BBA3970 Q28606732-26A6CE04-C66F-42CF-884D-5F3C9E1DB3ED Q30389282-92D82348-065A-4A25-BA0C-B2D5A17CB547 Q30444198-B1D717C2-2966-4DEC-8B39-6C9AABADDC6A Q30453975-7605545A-25FC-487F-A3E7-06FDA251744A Q33157937-D27A18A5-ACD6-42A2-AC47-85A47DAFBD7D Q33365961-89620C9A-3ACE-4EF8-82A3-5373467FD91F Q33374135-4E615357-1E0F-47D7-A869-2C03727BBF74 Q33394544-7117EB4F-B05C-4129-931C-BD253BFBC53C Q33395929-4F3A8DA7-5DC2-48C3-A482-9BF0BDDE8DB5 Q33407719-1FA29B54-57D0-4B54-94AB-79E82E56DD42 Q33410537-187523EB-F8DC-47B9-8E0B-73C684A0614B Q33418008-D5F66278-1767-47C6-B488-7138A4486979 Q33424397-B2CCE31E-07B3-40DE-A467-7D9E3E6CA72B Q33429063-DE7CD18A-3E8D-4E87-BD2B-7C5FC99DB021 Q33430833-D0907A51-8CE6-4C4D-970B-44B37F5410FF

P2860

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

http://www.wikidata.org/entity/Q43040369

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Adherence to combination thera ...... ents with chronic hepatitis C.

@en

Adherence to combination thera ...... ents with chronic hepatitis C.

@nl

type

label

Adherence to combination thera ...... ents with chronic hepatitis C.

@en

Adherence to combination thera ...... ents with chronic hepatitis C.

@nl

prefLabel

Adherence to combination thera ...... ents with chronic hepatitis C.

@en

Adherence to combination thera ...... ents with chronic hepatitis C.

@nl

P1433

Q43040369-0AB46E12-55D5-4675-A865-B364C45A6289

P1476

Q43040369-A9EED31E-83F3-4E37-8393-660CA43D95AC

P2093

Q43040369-0B028D4D-D18D-41B5-A6BA-337E102898D4

Q43040369-13996498-5A06-4032-AD9E-6662B548563D

Q43040369-7091D736-BD32-4495-BA59-D6848BBF44F6

Q43040369-7466FE45-E4A4-411A-9567-FFDE40A7C1C2

Q43040369-A8E16BD4-C4AD-45E3-A4D9-DF7828EFC82D

Q43040369-D0E93F00-AF4E-4630-97A6-C89A289CF75E

Q43040369-E71D1D34-EE6B-4340-83B6-60859DF1E553

Q43040369-ECE36159-5A14-4E73-B71C-A8585DF212B1

Q43040369-F6C810D8-4805-4A9B-B4D6-1A9B17E058C0

Q43040369-F7456B85-FA53-42FC-B083-169BC1C86360

P304

Q43040369-52E97ED9-4D16-48CD-9151-F1D83CAA440C

P31

Q43040369-E5FBDAEA-F84D-470D-A425-157B5AE43D8F

P356

Q43040369-0ABF3BC0-40CF-4D34-85AD-8F0B18620561

P407

Q43040369-9C1C11BF-2320-4775-B5EA-7E58DEBC546E

P433

Q43040369-9EA25DD8-6173-4F41-A118-EB4D43C77904

P478

Q43040369-829D4B95-EAC5-426B-A396-D8135834BEE8

P50

Q43040369-0C393159-B027-4318-87DE-7C79639796C7

Q43040369-F421563E-475E-491F-ACC9-F7F1AE3CB287

P577

Q43040369-6F6B7ED7-4BF6-4D2C-B083-437D21FA0072

P698

Q43040369-D7802901-EEC8-4AC2-939D-5620E6BE6CEA

P356

GAST.2002.35950

P1433

Gastroenterology

P1476

Adherence to combination thera ...... ients with chronic hepatitis C

@en

P2093

Carmen Mak

http://www.w3.org/2001/XMLSchema#string

Christian Trepo

http://www.w3.org/2001/XMLSchema#string

International Hepatitis Interventional Therapy Group

http://www.w3.org/2001/XMLSchema#string

Janice K Albrecht

http://www.w3.org/2001/XMLSchema#string

Jean-Jacques Garaud

http://www.w3.org/2001/XMLSchema#string

John G McHutchison

http://www.w3.org/2001/XMLSchema#string

Karen L Lindsay

http://www.w3.org/2001/XMLSchema#string

Keyur Patel

http://www.w3.org/2001/XMLSchema#string

Michael Manns

http://www.w3.org/2001/XMLSchema#string

William M Lee

http://www.w3.org/2001/XMLSchema#string

P304

1061-1069

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/GAST.2002.35950

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Thierry Poynard

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12360468

http://www.w3.org/2001/XMLSchema#string